MYO1F and neoplasm: More mechanistic studies (e.g., genetic and epigenetic regulation) using immune-competent models are needed to understand the functional impact of the prioritized regulators of melanoma (e.g., MYO1F and ZNF180) on tumor progression and immune modulation.